Atopic Dermatitis Is Systemic, and 'Doing Nothing' Has a Cost
Dermatology Times argues untreated atopic dermatitis isn't neutral: reframed as a systemic inflammatory disease, inaction carries its own risks beyond skin.
Topic
Jak Inhibitors
Topic
Jak Inhibitors
Indian Dermatology Online Journal Publishes Comprehensive Abrocitinib Review
A comprehensive abrocitinib review in the Indian Dermatology Online Journal is now indexed on Ovid, widening access for dermatolo…
JAAD Review Flags Kaposi Sarcoma as Emerging JAK Inhibitor Signal
A JAAD systematic review published online October 17, 2026 consolidates case reports of Kaposi sarcoma emerging during Janus kina…
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2, Level Up Data
Dermatology Times spotlights three atopic dermatitis storylines from EADV 2026 in Europe: the biologic tilrekimig, RAC2 pathway i…
CXCL10 Identified as Response Biomarker for Ruxolitinib Cream in Vitiligo
CXCL10 correlates with clinical response to ruxolitinib cream in vitiligo, per the Phase 2 TRuE-V mechanism-of-action study publi…
Topical or Oral JAK Inhibitors for Vitiligo: The Choice Problem
Dermatology Times examines how clinicians should choose between topical and oral JAK inhibitors for vitiligo as systemic options…
JAK Switch Decisions Move to Center Stage in Atopic Dermatitis
Three FDA-approved JAK-pathway agents now compete for atopic dermatitis prescriptions, and a new managed-care review weighs how d…
Eczema Molluscatum Reported in AD Patient on Upadacitinib, Methotrexate
A Cureus case report describes eczema molluscatum in an adult with atopic dermatitis on upadacitinib and methotrexate, renewing f…
Wiley review maps skin and gut microbiome in atopic dermatitis
Wiley Online Library indexes a peer-reviewed review pairing skin and gut microbiome mechanisms with therapeutic opportunities in…
Precision Medicine in Atopic Dermatitis: Where the Field Stands Now
A Dermatology Times review maps precision medicine's uneven progress in atopic dermatitis: targeted drugs are here, patient-level…